Fundz

Who to call at bioAffinity Technologies, and when

Fundz watches for the moments bioAffinity Technologies starts buying, and tells you who to reach.

  • An alert the day bioAffinity Technologies raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at bioAffinity Technologies, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

bioAffinity Technologies and AvMEDICAL Form Distribution Partnership to Expand Access to Lung Cancer Testing for Veterans.

Sep 30, 2026

Contract Type

partnership

San AntonioBiotechnologyHealth CareTherapeuticsHealth Diagnostics

Description

bioAffinity Technologies has established a partnership with AvMEDICAL to promote its noninvasive CyPath® Lung Cancer Test. The collaboration aims to enhance access for veterans through federal healthcare distribution channels, showcased at the NAVREF conference.

Company Information

Company

bioAffinity Technologies

Location

San Antonio, Texas, United States

About

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

Related People

Maria
Senior decision-maker at this company
••••••••@••••••••

See Maria's verified email →

Dallas
Senior decision-maker at this company
••••••••@••••••••

See Dallas's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for bioAffinity Technologies's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

bioAffinity Technologies signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.